Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their...

Area of Science:

• Hematology
• Molecular Biology
• Oxidative Stress Research

Background:

• Low-risk myelodysplastic syndromes (MDS) frequently lead to iron overload.
• Iron overload in MDS patients causes significant oxidative stress within the bone marrow (BM).
• This oxidative stress contributes to hematopoietic cell dysfunction.

Purpose of the Study:

• To investigate if deferasirox (DFX) chelation therapy can mitigate oxidative stress consequences.
• To determine if DFX treatment improves bone marrow (BM) cell functionality in MDS patients.
• To assess the impact of DFX on DNA oxidation and hematopoietic differentiation capacity.

Main Methods:

• Analysis of 13 iron-overloaded MDS patients' BM samples before and after DFX treatment.
• Multiparametric flow cytometry to measure intracellular reactive oxygen species (ROS), DNA oxidation, and double-strand breaks.
• Colony-forming unit (CFU) assays to evaluate hematopoietic differentiation capacity.

Main Results:

• MDS patients exhibited elevated intracellular ROS and DNA oxidative damage in BM cells compared to healthy donors.
• DFX treatment led to a significant decrease in DNA oxidative damage.
• Hematopoietic differentiation capacity, assessed by CFU assays, showed improvement after DFX treatment, indicated by a reduced cluster/CFU ratio.

Conclusions:

• Bone marrow (BM) cells in MDS patients experience heightened oxidative stress and impaired hematopoietic differentiation.
• Deferasirox (DFX) treatment demonstrates a capacity to partially ameliorate these adverse conditions.
• DFX therapy may offer a beneficial approach for managing oxidative stress and improving hematopoietic function in MDS.